Aliases & Classifications for Melanoma

About this section

Aliases & Descriptions for Melanoma:

Name: Melanoma 10 47 12 36 35 65
Malignant Melanoma 10 24
 
Cutaneous Melanoma 65
Naevocarcinoma 10

Classifications:



External Ids:

Disease Ontology10 DOID:1909
MeSH36 D008545
NCIt42 C3224
ICD1027 D03.9
UMLS65 C0025202

Summaries for Melanoma

About this section
MedlinePlus:35 Melanoma is the most serious type of skin cancer. often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. most melanomas have a black or black-blue area. melanoma may also appear as a new mole. it may be black, abnormal, or "ugly looking." thinking of "abcde" can help you remember what to watch for: asymmetry - the shape of one half does not match the other border - the edges are ragged, blurred or irregular color - the color is uneven and may include shades of black, brown and tan diameter - there is a change in size, usually an increase evolving - the mole has changed over the past few weeks or months surgery is the first treatment of all stages of melanoma. other treatments include chemotherapy and radiation, biologic, and targeted therapies. biologic therapy boosts your body's own ability to fight cancer. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

MalaCards based summary: Melanoma, also known as malignant melanoma, is related to ocular melanoma and malignant breast melanoma, and has symptoms including pruritus, pruritus and exanthema. An important gene associated with Melanoma is MAGEA4 (MAGE Family Member A4). The drugs temozolomide and carmustine have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and brain.

Disease Ontology:10 A cell type cancer that has material basis in abnormally proliferating cells derived from melanocytes which are found in skin, the bowel and the eye.

Novus Biologicals:48 Melanoma is a malignant tumor that results from uncontrolled growth of pigmented cells, called melanocytes. Several types of melanoma exist, including superficial spreading melanoma, nodular melanoma and lentigo melanoma. Melanoma diagnosis is traditionally supported by the presence of the S-100 protein marker and HMB-45, however research has determined the sensitivity and specificity of three novel antibodies as markers for melanoma: Mitf, Melan-A and tyrosinase.

Wikipedia:68 Melanoma, also known as malignant melanoma, is a type of cancer that develops from the... more...

Related Diseases for Melanoma

About this section

Diseases related to Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 649)
idRelated DiseaseScoreTop Affiliating Genes
1ocular melanoma34.3MAGEA4, MAGEC1
2malignant breast melanoma33.9MCAM, MITF
3choroid spindle cell melanoma33.8CDK4, CDKN2A, MIA, MITF
4angiolipoma30.5CDK4, CDKN2A
5glioma30.3CDK4, CDKN2A, GPNMB
6astrocytoma30.0CDK4, CDKN2A, GPNMB
7epidermolysis bullosa29.3MAGEA1, MAGEA10, MAGEA11, MAGEA2, MAGEA2B, MAGEA3
8skin melanoma12.3
9malignant melanoma, somatic12.2
10uveal melanoma12.2
11acral lentiginous melanoma12.2
12amelanotic melanoma12.1
13nodular malignant melanoma12.1
14mucosal melanoma12.0
15melanoma and neural system tumor syndrome12.0
16lentigo maligna melanoma12.0
17malignant spindle cell melanoma12.0
18pancreatic cancer/melanoma syndrome12.0
19superficial spreading melanoma12.0
20posterior uveal melanoma12.0
21melanoma-associated retinopathy12.0
22melanoma, cutaneous malignant 812.0
23melanoma of soft parts12.0
24melanoma, cutaneous malignant, 912.0
25melanoma, cutaneous malignant, 211.9
26melanoma, cutaneous malignant, 311.9
27melanoma, cutaneous malignant, 611.9
28melanoma, cutaneous malignant, 511.9
29vulvar melanoma11.9
30primary gastrointestinal melanoma11.9
31meningeal melanoma11.9
32spinal cord melanoma11.9
33gallbladder melanoma11.9
34epithelioid cell melanoma11.9
35malignant choroid melanoma11.9
36malignant iris melanoma11.9
37primary malignant melanoma of the cervix11.9
38ciliary body spindle cell melanoma11.9
39balloon cell malignant melanoma11.9
40orbital melanoma11.9
41melanoma metastasis11.9
42iris spindle cell melanoma11.9
43ovarian melanoma11.8
44melanoma, cutaneous malignant 1011.8
45necrotic uveal melanoma11.8
46malignant eyelid melanoma11.8
47malignant conjunctiva melanoma11.8
48primary melanoma of the central nervous system11.8
49malignant anus melanoma11.8
50cervix melanoma11.8

Graphical network of the top 20 diseases related to Melanoma:



Diseases related to melanoma

Symptoms for Melanoma

About this section

UMLS symptoms related to Melanoma:


pruritus, exanthema

Drugs & Therapeutics for Melanoma

About this section

FDA approved drugs:

(show all 12)
id Drug Name Active Ingredient(s)15 Company Approval Date
1
Erivedge15 41 VISMODEGIB Genentech January 2012
FDA Label: Erivedge
Disease/s that Drug Treats:basal cell carcinoma
Indications and Usage:15 ERIVEDGE (vismodegib) capsule is a hedgehog pathway inhibitor indicatedfor the treatment of adults with metastatic basal cell carcinoma, or with locallyadvanced basal cell carcinoma that has recurred following surgery or who arenot candidates for surgery, and who are not candidates for radiation. (1)
DrugBank Targets:13 1. Smoothened homolog
Mechanism of Action:15 
Target: hedgehog (Hh) signaling pathway
Action: innhibitor
FDA: Vismodegib is an inhibitor of the Hedgehog pathway. Vismodegib binds to and inhibitsSmoothened, a transmembrane protein involved in Hedgehog signal transduction.
2
Intron A15 41 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
FDA Label: Intron A
Disease/s that Drug Treats:non-Hodgkin's lymphoma/ malignant melanoma / Hepatitis C
Indications and Usage:15 Hairy Cell Leukemia INTRON® A is indicated for the treatment of patients 18 years ofage or older with hairy cell leukemia.Malignant Melanoma INTRON A is indicated as adjuvant to surgical treatment inpatients 18 years of age or older with malignant melanoma who are free of disease butat high risk for systemic recurrence, within 56 days of surgery.Follicular Lymphoma INTRON A is indicated for the initial treatment of clinicallyaggressive (see Clinical Pharmacology) follicular Non-Hodgkin’s Lymphoma inconjunction with anthracycline-containing combination chemotherapy in patients 18years of age or older. Efficacy of INTRON A therapy in patients with low-grade, lowtumorburden follicular Non-Hodgkin’s Lymphoma has not been demonstrated.Condylomata Acuminata INTRON A is indicated for intralesional treatment of selectedpatients 18 years of age or older with condylomata acuminata involving externalsurfaces of the genital and perianal areas (see DOSAGE AND ADMINISTRATION).The use of this product in adolescents has not been studied.AIDS-Related Kaposi's Sarcoma INTRON A is indicated for the treatment of selectedpatients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihoodof response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immunesystem as indicated by total CD4 count.Chronic Hepatitis C INTRON A is indicated for the treatment of chronic hepatitis C inpatients 18 years of age or older with compensated liver disease who have a history ofblood or blood-product exposure and/or are HCV antibody positive. Studies in thesepatients demonstrated that INTRON A therapy can produce clinically meaningful effectson this disease, manifested by normalization of serum alanine aminotransferase (ALT)and reduction in liver necrosis and degeneration.A liver biopsy should be performed to establish the diagnosis of chronic hepatitis.Patients should be tested for the presence of antibody to HCV. Patients with othercauses of chronic hepatitis, including autoimmune hepatitis, should be excluded. Priorto initiation of INTRON A therapy, the physician should establish that the patient hascompensated liver disease. The following patient entrance criteria for compensated liverdisease were used in the clinical studies and should be considered before INTRON Atreatment of patients with chronic hepatitis C: No history of hepatic encephalopathy, variceal bleeding, ascites, or otherclinical signs of decompensation Bilirubin Less than or equal to 2 mg/dL Albumin Stable and within normal limits Prothrombin Time Less than 3 seconds prolonged WBC Greater than or equal to 3000/mm3 Platelets Greater than or equal to 70,000/mm3Serum creatinine should be normal or near normal.Prior to initiation of INTRON A therapy, CBC and platelet counts should beevaluated in order to establish baselines for monitoring potential toxicity. These testsshould be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, andmonthly thereafter. Serum ALT should be evaluated at approximately 3-month intervalsto assess response to treatment (see DOSAGE AND ADMINISTRATION).Patients with preexisting thyroid abnormalities may be treated if thyroidstimulatinghormone (TSH) levels can be maintained in the normal range by medication.TSH levels must be within normal limits upon initiation of INTRON A treatment and TSHtesting should be repeated at 3 and 6 months (see PRECAUTIONS, LaboratoryTests).INTRON A in combination with REBETOL® is indicated for the treatment ofchronic hepatitis C in patients 3 years of age and older with compensated liver diseasepreviously untreated with alpha interferon therapy and in patients 18 years of age andolder who have relapsed following alpha interferon therapy. See REBETOL prescribinginformation for additional information. Chronic Hepatitis B INTRON A is indicated for the treatment of chronic hepatitis B inpatients 1 year of age or older with compensated liver disease. Patients who have beenserum HBsAg positive for at least 6 months and have evidence of HBV replication(serum HBeAg positive) with elevated serum ALT are candidates for treatment. Studiesin these patients demonstrated that INTRON A therapy can produce virologic remissionof this disease (loss of serum HBeAg) and normalization of serum aminotransferases.INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy beperformed to establish the presence of chronic hepatitis and the extent of liver damage.The physician should establish that the patient has compensated liver disease. Thefollowing patient entrance criteria for compensated liver disease were used in theclinical studies and should be considered before INTRON A treatment of patients withchronic hepatitis B: No history of hepatic encephalopathy, variceal bleeding, ascites, or othersigns of clinical decompensation Bilirubin Normal Albumin Stable and within normal limits Prothrombin Time Adults less than 3 seconds prolongedPediatrics less than or equal to 2 seconds prolonged WBC Greater than or equal to 4000/mm3 Platelets Adults greater than or equal to 100,000/mm3Pediatrics greater than or equal to 150,000/mm3Patients with causes of chronic hepatitis other than chronic hepatitis B or chronichepatitis C should not be treated with INTRON A. CBC and platelet counts should beevaluated prior to initiation of INTRON A therapy in order to establish baselines formonitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2,4, 8, 12, and 16. Liver function tests, including serum ALT, albumin, and bilirubin,should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16. HBeAg, HBsAg, andALT should be evaluated at the end of therapy, as well as 3- and 6-months posttherapy,since patients may become virologic responders during the 6-month periodfollowing the end of treatment. In clinical studies in adults, 39% (15/38) of respondingpatients lost HBeAg 1 to 6 months following the end of INTRON A therapy. Ofresponding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.A transient increase in ALT greater than or equal to 2 times baseline value (flare)can occur during INTRON A therapy for chronic hepatitis B. In clinical trials in adultsand pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy andwas more frequent in responders (adults 63%, 24/38; pediatrics 59%, 10/17) than innonresponders (adults 27%, 13/48; pediatrics 35%, 19/55). However, in adults andpediatrics, elevations in bilirubin greater than or equal to 3 mg/dL (greater than or equalto 2 times ULN) occurred infrequently (adults 2%, 2/86; pediatrics 3%, 2/72) duringtherapy. When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinicalsymptomatology and liver function tests including ALT, prothrombin time, alkalinephosphatase, albumin, and bilirubin, should be monitored at approximately 2-weekintervals (see WARNINGS).
DrugBank Targets:13 1. Interferon alpha/beta receptor 2;2. Interferon alpha/beta receptor 1
Mechanism of Action:15 
Target: intracellular oncogene expression, natural killer and cytotoxic T-cells, microphage, cytokine production
Action: stimulation, induction (unspecified effects on oncogene expression)
FDA: -
3
Keytruda15 41 PEMBROLIZUMAB Merck September 2014
FDA Label: Keytruda
Disease/s that Drug Treats:unresectable or metastatic melanoma
Indications and Usage:15 KEYTRUDA is a human programmed death receptor-1 (PD-1)-blockingantibody indicated for the treatment of patients with unresectable ormetastatic melanoma and disease progression following ipilimumaband, if BRAF V600 mutation positive, a BRAF inhibitor.This indication is approved under accelerated approval based on tumorresponse rate and durability of response. An improvement in survivalor disease-related symptoms has not yet been established. Continuedapproval for this indication may be contingent upon verification anddescription of clinical benefit in the confirmatory trials. (1)
DrugBank Targets:13 1. Programmed cell death protein 1
Mechanism of Action:15 
Target: PD-1 receptor
Action: blocks interaction withPD-L1 and PD-L2
FDA: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cellproliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction withPD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including theanti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted indecreased tumor growth.
4
Mekinist15 41 TRAMETINIB DIMETHYL SULFOXIDE GlaxoSmithKline May of 2013
FDA Label: Mekinist
Disease/s that Drug Treats:unresectable or metastatic melanoma with BRAF V600E or V600K mutations
Indications and Usage:15 MEKINIST is a kinase inhibitor indicated as a single agent and incombination with dabrafenib for the treatment of patients with unresectable ormetastatic melanoma with BRAF V600E or V600K mutations as detected byan FDA-approved test. The use in combination is based on the demonstrationof durable response rate. Improvement in disease-related symptoms or overallsurvival has not been demonstrated for MEKINIST in combination withdabrafenib. (1, 14.1)Limitation of use: MEKINIST as a single agent is not indicated for treatmentof patients who have received prior BRAF-inhibitor therapy. (1)
DrugBank Targets:13 1. Dual specificity mitogen-activated protein kinase kinase 1;2. Dual specificity mitogen-activated protein kinase kinase 2
Mechanism of Action:15 
Target: mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase
Action: inhibitor
FDA: Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1(MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity. MEK proteins areupstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotescellular proliferation. BRAF V600E mutations result in constitutive activation of the BRAFpathway which includes MEK1 and MEK2. Trametinib inhibits BRAF V600 mutation-positivemelanoma cell growth in vitro and in vivo.Trametinib and dabrafenib target two different tyrosine kinases in the RAS/RAF/MEK/ERKpathway. Use of trametinib and dabrafenib in combination resulted in greater growth inhibitionof BRAF V600 mutation-positive melanoma cell lines in vitro and prolonged inhibition of tumorgrowth in BRAF V600 mutation positive melanoma xenografts compared with either drug alone.
5
Odomzo15 41 SONIDEGIB PHOSPHATE Novartis Jul-15
FDA Label: Odomzo
Disease/s that Drug Treats:locally advanced basal cell carcinoma
Indications and Usage:15 ODOMZO is a hedgehog pathway inhibitor indicated for the treatment ofadult patients with locally advanced basal cell carcinoma (BCC) that hasrecurred following surgery or radiation therapy, or those who are notcandidates for surgery or radiation therapy. (1)
DrugBank Targets: -
Mechanism of Action:15 
Target: Smoothened
Action: inhibitor
FDA: Sonidegib is an inhibitor of the Hedgehog pathway. Sonidegib binds to and inhibits Smoothened, a transmembrane proteininvolved in Hedgehog signal transduction.
6
Opdivo15 41 NIVOLUMAB Bristol-Myers Squibb March 2015/ December 2014
FDA Label: Opdivo
Disease/s that Drug Treats:metastatic squamous non-small cell lung cancer/ unresectable or metastatic melanoma
Indications and Usage:15 OPDIVO is a programmed death receptor-1 (PD-1) blocking antibodyindicated for the treatment of patients with: unresectable or metastatic melanoma and disease progression followingipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. (1.1)This indication is approved under accelerated approval based on tumorresponse rate and durability of response. Continued approval for thisindication may be contingent upon verification and description of clinicalbenefit in the confirmatory trials. (1.1, 14.1) metastatic squamous non-small cell lung cancer with progression on orafter platinum-based chemotherapy. (1.2)
DrugBank Targets:13 1. Programmed cell death protein 1
Mechanism of Action:15 
Target: PD-1 receptor
Action: blocker of interaction with PD-L1 and PD-L2
FDA: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibitsT-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in sometumors and signaling through this pathway can contribute to inhibition of active T-cell immunesurveillance of tumors. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibodythat binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1pathway-mediated inhibition of the immune response, including the anti-tumor immuneresponse. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumorgrowth.
7
Proleukin15 41 ALDESLEUKIN Chiron January 1998
FDA Label: Proleukin
Disease/s that Drug Treats:Metastatic melanoma
Indications and Usage:15 Proleukin® (aldesleukin) is indicated for the treatment of adults with metastatic renal cellcarcinoma (metastatic RCC).Proleukin is indicated for the treatment of adults with metastatic melanoma.Careful patient selection is mandatory prior to the administration of Proleukin. See“CONTRAINDICATIONS”, “WARNINGS” and “PRECAUTIONS” sections regarding patientscreening, including recommended cardiac and pulmonary function tests and laboratorytests.Evaluation of clinical studies to date reveals that patients with more favorable ECOGperformance status (ECOG PS 0) at treatment initiation respond better to Proleukin, with ahigher response rate and lower toxicity (See “CLINICAL PHARMACOLOGY” section,“CLINICAL STUDIES” section and “ADVERSE REACTIONS” section). Therefore, selectionof patients for treatment should include assessment of performance status.Experience in patients with ECOG PS >1 is extremely limited.
DrugBank Targets:13 1. Interleukin-2 receptor subunit beta;2. Interleukin-2 receptor subunit alpha;3. Cytokine receptor common subunit gamma
Mechanism of Action:15 
Target: human cells
Action: enhancer of immune response and strnaght ( lymphocytemitogenesis, growth of human interleukin-2 dependent cell lines, lymphocyte cytotoxicity, induction of killer cell activity and interferon-gamma production)
FDA: Proleukin® (aldesleukin) has been shown to possess the biological activities of human nativeinterleukin-2.1,2 In vitro studies performed on human cell lines demonstrate theimmunoregulatory properties of Proleukin, including: a) enhancement of lymphocytemitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines;b) enhancement of lymphocyte cytotoxicity; c) induction of killer cell (lymphokine-activated(LAK) and natural (NK)) activity; and d) induction of interferon-gamma production.The in vivo administration of Proleukin in animals and humans produces multipleimmunological effects in a dose dependent manner. These effects include activation ofcellular immunity with profound lymphocytosis, eosinophilia, and thrombocytopenia, and theproduction of cytokines including tumor necrosis factor, IL-1 and gamma interferon. 3 In vivoexperiments in murine tumor models have shown inhibition of tumor growth.4 The exactmechanism by which Proleukin mediates its antitumor activity in animals and humans isunknown.
8
Sylatron15 41 PEGINTERFERON ALFA-2B Merck April 2011
FDA Label: Sylatron
Disease/s that Drug Treats:melanoma
Indications and Usage:15 PegIntron is an antiviral indicated for treatment of Chronic Hepatitis C(CHC) in patients with compensated liver disease. (1.1)
DrugBank Targets:13 1. Interferon alpha/beta receptor 1;2. Interferon alpha/beta receptor 2
Mechanism of Action:15 
Target: innate antiviral immune response
Action: inducer
FDA: Pegylated recombinant human interferon alfa-2b is an inducer of the innate antiviral immune response [see Microbiology (12.4)].
9
Tafinlar15 41 DABRAFENIB MESYLATE GlaxoSmithKline May 2013
FDA Label: Tafinlar
Disease/s that Drug Treats:unresectable or metastatic melanoma with BRAF V600E mutation
Indications and Usage:15  TAFINLAR is a kinase inhibitor indicated as a single agent for thetreatment of patients with unresectable or metastatic melanoma withBRAF V600E mutation as detected by an FDA-approved test. (1.1, 2.1) TAFINLAR in combination with trametinib is indicated for the treatmentof patients with unresectable or metastatic melanoma with BRAF V600Eor V600K mutations as detected by an FDA-approved test. The use incombination is based on the demonstration of durable response rate.Improvement in disease-related symptoms or overall survival has notbeen demonstrated for TAFINLAR in combination with trametinib. (1.2,2.1, 14.2)Limitation of Use: TAFINLAR is not indicated for treatment of patients withwild-type BRAF melanoma. (1.3, 5.2)
DrugBank Targets:13 1. Serine/threonine-protein kinase B-raf;2. RAF proto-oncogene serine/threonine-protein kinase;3. Serine/threonine-protein kinase SIK1;4. Serine/threonine-protein kinase Nek11;5. LIM domain kinase 1
Mechanism of Action:15 
Target: some mutated forms of BRAF kinases, wild-type BRAF and CRAF kinases
Action: inhibitor
FDA: Dabrafenib is an inhibitor of some mutated forms of BRAF kinases with in vitro IC50 values of0.65, 0.5, and 1.84 nM for BRAF V600E, BRAF V600K, and BRAF V600D enzymes,respectively. Dabrafenib also inhibits wild-type BRAF and CRAF kinases with IC50 values of 3.2and 5.0 nM, respectively, and other kinases such as SIK1, NEK11, and LIMK1 at higherconcentrations. Some mutations in the BRAF gene, including those that result in BRAF V600E,can result in constitutively activated BRAF kinases that may stimulate tumor cell growth [seeIndications and Usage (1)]. Dabrafenib inhibits BRAF V600 mutation-positive melanoma cellgrowth in vitro and in vivo.Dabrafenib and trametinib target two different tyrosine kinases in the RAS/RAF/MEK/ERKpathway. Use of dabrafenib and trametinib in combination resulted in greater growth inhibitionof BRAF V600 mutation-positive melanoma cell lines in vitro and prolonged inhibition of tumorgrowth in BRAF V600 mutation positive melanoma xenografts compared with either drug alone.
10
Yervoy15 41 IPILIMUMAB Bristol-Myers Squibb March 2011
FDA Label: Yervoy
Disease/s that Drug Treats:metastatic melanoma
Indications and Usage:15 YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blockingantibody indicated for the treatment of unresectable or metastaticmelanoma. (1)
DrugBank Targets:13 1. Cytotoxic T-lymphocyte protein 4
Mechanism of Action:15 
Target: CTLA-4
Action: blocker of interation with CD80/CD86
FDA: CTLA-4 is a negative regulator of T-cell activity. Ipilimumab is a monoclonal antibody thatbinds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, CD80/CD86. Blockadeof CTLA-4 has been shown to augment T-cell activation and proliferation, including theactivation and proliferation of tumor infiltrating T-effector cells. Inhibition of CTLA-4 signalingcan also reduce T-regulatory cell function, which may contribute to a general increase in T cellresponsiveness, including the anti-tumor immune response.
11
Zelboraf15 41 VEMURAFENIB Roche August of 2011
FDA Label: Zelboraf
Disease/s that Drug Treats:BRAF + melanoma
Indications and Usage:15 ZELBORAF® is a kinase inhibitor indicated for the treatment of patients withunresectable or metastatic melanoma with BRAF V600E mutation as detectedby an FDA-approved test. (1, 2.1)Limitation of Use: ZELBORAF is not indicated for treatment of patients withwild-type BRAF melanoma. (2.1, 5.2)
DrugBank Targets:13 1. Serine/threonine-protein kinase B-raf
Mechanism of Action:15 
Target: some mutated forms of BRAF serinethreoninekinase
Action: inhibitor
FDA: Vemurafenib is a low molecular weight, orally available inhibitor of some mutated forms of BRAF serinethreoninekinase, including BRAF V600E. Vemurafenib also inhibits other kinases in vitro such as CRAF,ARAF, wild-type BRAF, SRMS, ACK1, MAP4K5, and FGR at similar concentrations. Some mutations in theBRAF gene including V600E result in constitutively activated BRAF proteins, which can cause cellproliferation in the absence of growth factors that would normally be required for proliferation. Vemurafenibhas anti-tumor effects in cellular and animal models of melanomas with mutated BRAF V600E.
12
Opdivo15 NIVOLUMAB Bristol-Myers Squibb March 2015
FDA Label: Opdivo
Disease/s that Drug Treats:metastatic squamous non-small cell lung cancer
Indications and Usage:15 OPDIVO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with: * unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. (1.1) This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. (1.1, 14.1) * metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy. (1.2)
DrugBank Targets:13 Programmed cell death protein 1
Mechanism of Action:15 
Target: PD-1 receptor
Action: blocks its interaction with PD-L1 and PD-L2
FDA: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.

Drugs for Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 567)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
TriamcinoloneapprovedPhase 4, Phase 2, Phase 3448124-94-731307
Synonyms:
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione
11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11beta,16alpha,17alpha,21-Tetrahydroxy-9alpha-fluoro-1,4-pregnadiene-3,20-dione
124-94-7
4-08-00-03629 (Beilstein Handbook Reference)
83474-03-7
9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-16-alpha-hydroxyprednisolone
9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy
9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17alpha,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-hydroxyprednisolone
9α-fluoro-16α-hydroxyprednisolone
AC-2072
AC1L1LDH
AC1Q5HJC
Adcortyl
Allernaze
Aristocort
Aristocort A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
BPBio1_000154
BRD-K77554836-001-03-3
BRN 2341955
BSPBio_000140
Bio-0662
C21H27FO6
CHEMBL1451
CID31307
CL 19823
Celeste
Cinolone
Cinolone-T
D00385
D014221
DB00620
Delphicort
EINECS 204-718-7
EU-0101179
Fluoxiprednisolone
Fluoxyprednisolone
Flutex
Fougera
HMS1568G22
HMS2090D12
HSDB 3194
Kenacort
Kenacort (TN)
Kenacort-A
Kenacort-AG
Kenacort-Ag
Kenalog
Kenalog in Orabase
Kenalog-10
Kenalog-40
Kenalog-H
LS-698
Ledercort
Lopac0_001179
MLS000028542
MLS001066543
 
MLS002695935
MolPort-002-528-981
Mycolog
NCGC00021580-03
NCGC00021580-04
NCGC00021580-05
NCGC00021580-06
NCGC00021580-07
NCI60_000750
NSC 13397
NSC13397
Nasacort
Nasacort Aq
Nasacort Hfa
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Pregna-1,4-diene-3,20-dio
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)
Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI)
Prestwick0_000120
Prestwick1_000120
Prestwick2_000120
Prestwick3_000120
Prestwick_438
Rodinolone
S1933_Selleck
SK-Triamcinolone
SMP1_000300
SMR000058333
SPBio_002079
Sk-Triamcinolone
T6376_SIGMA
TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7))
Tiamcinolonum
Tiamcinolonum [INN-Latin]
Tri-Nasal
Triacet
Triacort
Triam-Tablinen
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
Triamcinolone (JP15/USP/INN)
Triamcinolone Acetonide
Triamcinolone [USAN:INN:BAN:JAN]
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Trianex
Triatex
Tricortale
Triderm
Triesence
Trilone
Tristoject
Trymex
UNII-1ZK20VI6TY
Vetalog
Volon
Volon A
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ
ZINC03882036
droxypregna-1,4-diene-3,20-dione
ione
nchembio.2007.53-comp7
triamcinolone
2
RanibizumabapprovedPhase 4, Phase 3, Phase 2, Phase 1460347396-82-1459903
Synonyms:
347396-82-1
D05697
Lucentis
Lucentis (TN)
 
Ranibizumab
Ranibizumab (USAN/INN)
Ranibizumab (genetical recombination)
Ranibizumab (genetical recombination) (JAN)
ranibizumab
rhuFab V2
3
Dasatinibapproved, investigationalPhase 4, Phase 2, Phase 1268302962-49-83062316
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
Anh. dasatinib
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
DB01254
Dasatinib
Dasatinib (USAN)
Dasatinib (anh.)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
 
Dasatinibum
EC-000.2122
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NSC-732517
NSC732517
S1021_Selleck
SPRYCEL (TN)
Sprycel
Spyrcel
UNII-X78UG0A0RN
dasatinib
dasatinibum
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
4
Dacarbazineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 14114342-03-45351166
Synonyms:
(5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
(Dimethyltriazeno)imidazolecarboxamide
37626-23-6
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide
4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide
4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide
4-(Dimethyltriazeno)imidazole-5-c arboxamide
4-(Dimethyltriazeno)imidazole-5-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide
4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide
4342-03-4
5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide
5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide
5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide
5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide
5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide
5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide
5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide
5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide
5-(Dimethyltriazeno)-4-imidazolecarboxamide
5-(Dimethyltriazeno)imidazole-4-carboxamide
5-(Dimethyltriazeno)imidazole-4-carboximide
5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide
5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide
94361-71-4
AC1NQXVV
AC1NS01W
AC1NS4BN
AI3-52825
BPBio1_000428
BRD-K35520305-001-07-8
BSPBio_000388
BSPBio_002091
Biocarbazin
Biocarbazine
Biocarbazine R
C6H10N6O
CAS-891986
CCRIS 190
CHEBI:4305
CHEMBL476
CID5281007
CID5351166
CID5353562
Carboxamide, Dimethyl Imidazole
D00288
D003606
D2390_SIGMA
D3634
DB00851
DIC
DTCI
DTIC
DTIC Dome
DTIC, DTIC-Dome, Dacarbazine
DTIC-Dome
DTICDome
DTIE
Dacarbazin
Dacarbazina
Dacarbazine
Dacarbazine (JAN/USP/INN)
Dacarbazine [USAN:INN:BAN:JAN]
Dacarbazino
Dacarbazino [INN-Spanish]
Dacarbazinum
Dacarbazinum [INN-Latin]
 
Dacatic
Decarbazine
Deticene
Di-me-triazenoimidazolecarboxamide
Di-methyl-triazenoimidazolecarboxamide
Dimethyl Imidazole Carboxamide
Dimethyl Triazeno Imidazole Carboxamide
Dimethyltriazenoimidazolecarboxamide
DivK1c_000326
Dtic-Dome
Dtic-Dome (TN)
Dtic-dome (tn)
EINECS 224-396-1
HE1150000
HMS1569D10
HMS2090A20
HMS2091I20
HMS501A08
HSDB 3219
I06-2280
I14-1659
ICDMT
ICDT
IDI1_000326
Imidazole Carboxamide
Imidazole Carboxamide, Dimethyl
Imidazole carboxamide
KBio1_000326
KBio2_001364
KBio2_003932
KBio2_006500
KBio3_001311
KBioGR_000896
KBioSS_001364
LS-119
MLS001332543
MLS001332544
MolPort-003-666-153
MolPort-003-846-120
MolPort-006-709-420
NCGC00016986-01
NCGC00091861-01
NCGC00091861-02
NCGC00091861-03
NCGC00091861-04
NCI-C04717
NCI60_004053
NCIMech_000261
NINDS_000326
NIOSH/HE1150000
NPFAPI-05
NSC 45388
NSC-45388
NSC45388
Prestwick0_000574
Prestwick1_000574
Prestwick2_000574
Prestwick3_000574
Prestwick_904
S1221_Selleck
SMP2_000251
SMR000857131
SPBio_001075
SPBio_002607
SPECTRUM1500218
ST51014976
Spectrum2_001148
Spectrum3_000366
Spectrum4_000308
Spectrum5_000823
Spectrum_000884
UNII-7GR28W0FJI
WLN: T5M CNJ DVZ ENUNN1&1
dacarbazine
5
CisplatinapprovedPhase 4, Phase 3, Phase 1, Phase 2254015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatin
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinol-aq
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
6
Imiquimodapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 113199011-02-657469
Synonyms:
1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine
1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine
1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine
1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
1-isobutyl-1H-imidazo(4,5-c)quinolin-4-amine
1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
3M Brand of Imiquimod
4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline
4-Amino-1-isobutyl-1H-imidazo[4,5-c]quinoline
99011-02-6
AC-529
AC1L1N2I
AC1Q4YO9
Aldara
Aldara (TN)
Aldara, Imiquimod
BB_SC-2107
BIDD:GT0859
Beselna
C056493
CHEBI:36704
CHEMBL1282
CID57469
D02500
DB00724
DZ-2636
FT-0080222
HMS2090M14
I06-0624
 
I06-2289
I0747
I5159_SIGMA
IMIQUIMOD
Imiquimod
Imiquimod (JAN/USAN/INN)
Imiquimod [USAN:INN]
Imiquimod acetate
Imiquimodum
LS-178395
MLS000083577
MTD-39
MolPort-002-507-845
NCGC00070736-02
NSC369100
R 837
R-837
S 26308
S-26308
S1211_Selleck
SMR000048307
STK583860
TL8006059
TMX-101
UNII-P1QW714R7M
Vyloma
ZINC19632912
Zartra
Zyclara
imiquimod
7
NivolumabapprovedPhase 4, Phase 2, Phase 3, Phase 1198946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab
8
EverolimusapprovedPhase 4, Phase 2, Phase 11797159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Afinitor Disperz
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
VOTUBIA
Zortress
everolimus
9
Miconazoleapproved, investigationalPhase 4, Phase 2, Phase 1302622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
Desenex
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Makesense
Micantin (nitrate)
Micatin
 
Miconasil Nitrate
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Oravig
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
Rash Relief Antifungal
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
10
TrametinibapprovedPhase 4, Phase 3, Phase 2, Phase 1111871700-17-311707110
Synonyms:
GSK 1120212
GSK1120212
JTP 74057
JTP-74057
 
MEK Inhibitor GSK1120212
Mekinist
Trametinib Dimethyl Sulfoxide
Trametinibum
trametinib
11
Vorinostatapproved, investigationalPhase 4, Phase 2, Phase 1238149647-78-95311
Synonyms:
149647-78-9
1zz1
AC-1923
AC1L1K2K
BRD-K81418486-001-10-3
C111237
CCRIS 8456
CHEBI:45716
CHEMBL98
CID5311
D06320
DB02546
EC-000.2057
FT-0082592
LS-186548
LS-186997
LS-187780
MK-0683
MK0683
MLS001065855
Merck brand of Vorinostat
MolPort-003-850-293
N'-hydroxy-N-phenyloctanediamide
N-Hydroxy-N'-phenyl octanediamide
N-Hydroxy-N'-phenyloctanediamide
N-Hyrdroxy-N'-phenyloctanediamide
N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide
N-hydroxy-N'-phenyloctanediamide
N1-hydroxy-N8-phenyloctanediamide
NCGC00168085-02
 
NHNPODA
NSC-701852
NSC701852
OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE
Octanedioic acid hydroxyamide phenylamide
S1047_Selleck
SAHA
SAHA cpd
SAHA, Suberoylanilide hydroxamic acid
SHH
SKI390
SMR000486344
SW-064652
Suberanilohydroxamic acid
SuberoylaN/Aide hydroxamic acid
Suberoylanilide hydroxamic acid
UNII-58IFB293JI
Vorinostat
Vorinostat (JAN/USAN)
Vorinostat MSD
Vorinostat [USAN]
Vorinostatum
WIN64652
ZINC01543873
Zolinza
Zolinza (TN)
Zolinza, MK-0683, SAHA
m344
nchembio.275-comp2
nchembio.313-comp1
nchembio815-comp18
suberoylanilide hydroxamic acid
12
AldesleukinapprovedPhase 4, Phase 3, Phase 2, Phase 1, Phase 038785898-30-2
Synonyms:
IL-2
Interleukin-2 precursor
 
Proleukin
T-cell growth factor
TCGF
13
Sunitinibapproved, investigationalPhase 4, Phase 2, Phase 1486341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib Malate
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
14
Sorafenibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1671284461-73-0216239, 406563
Synonyms:
284461-73-0
4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide
4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide
4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide
4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE
AB1004622
AC-1674
AC1L50CF
BAX
BAY 43-9006
BAY 43-9006 (free base)
BAY 43-9006 tosylate salt
BAY 439006
BAY 54-9085 (tosylate salt)
BAY-43-0006
BAY-43-9006
BAY-54-9085
BAY43-9006
BRD-K23984367-001-01-8
Bio-0100
CHEBI:47228
CHEBI:50924
CHEMBL1336
CID216239
 
D08524
DB00398
DB07438
EN002709
I06-0856
K00597a
Kinome_766
LS-186067
LS-187021
LS-187788
MolPort-003-850-270
N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea
NCGC00167488-01
NSC-724772
NSC747971
Nexavar
STK627350
Sorafenib
Sorafenib (INN)
Sorafenib Tosylate
Sorafenib [INN]
Sorafenib tosylate
Sorafenibum
UNII-9ZOQ3TZI87
ZINC01493878
nchembio.117-comp17
sorafenib
sorafenibum
15
OlaparibapprovedPhase 4, Phase 1104763113-22-023725625
Synonyms:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
763113-22-0
937799-91-2
AKOS005145764
AZD 2281
AZD-2281
AZD2281
 
Acylpiperazine analogue, 47
CHEMBL521686
EC-000.2324
EN002690
FT-0083489
KU-0059436
KU-59436
Olaparib
Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281
S1060_Selleck
olaparib
16
Sirolimusapproved, investigationalPhase 4, Phase 2, Phase 1179753123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
17
CitalopramapprovedPhase 449459729-33-82771
Synonyms:
1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile
1,3-dihydro[3,4]benzofuran-5-carbonitrile
1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
59729-33-8
AB00513896
AC-12214
AC1L1EFH
AE-641/00603021
Akarin
BPBio1_000929
BRD-A47598013-004-02-0
BSPBio_000843
Bonitrile
C07572
C20H21FN2O
CHEBI:3723
CHEMBL549
CID2771
CPD000465669
Celapram
Celexa
Celius
Ciazil
Cilift
Cipram
Cipramil
Ciprapine
Citabax
Citadur
Citadur (TN)
Citalec
Citalopram
Citalopram (USP/INN)
Citalopram Hydrobromide
Citalopram [Celexa]
Citalopram [INN:BAN]
Citalopram hydrobromide
Citalopramum
Citalopramum [INN-Latin]
 
Citol
Citopam
Citox
Citrol
Cytalopram
D07704
DB00215
Dalsan
EINECS 261-891-1
Elopram
HMS2090O09
HMS2093A14
Humorup
I01-0382
InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
L001223
LS-84327
Lopac0_000258
Lu 10-171
Lu-10-171
MolPort-003-666-794
NCGC00015267-07
NCGC00025160-02
Nitalapram
Oropram
Perrigo Citalopram
Pramcit
Prestwick3_000692
Recital
SAM002589960
ST069372
STL058639
Seropram
Talam
Talohexal
Temperax
UNII-0DHU5B8D6V
Vodelax
Zentius
Zetalo
[3H]Citalopram
citalopram
18
Bortezomibapproved, investigational, experimentalPhase 4, Phase 2, Phase 1769179324-69-7387447, 93860
Synonyms:
179324-69-7
AC1L8TUW
Bortezomib
Bortezomib (JAN/USAN/INN)
CHEBI:287372
CHEBI:41143
CHEMBL325041
CID387447
D03150
DB07475
DPBA
FT-0082488
I14-3268
LDP-341
LDP341
LPD 341
LPD-341
 
MLN341
MolPort-003-845-298
N-[(1R)-1-(DIHYDROXYBORYL)-3-METHYLBUTYL]-N-(PYRAZIN-2-YLCARBONYL)-L-PHENYLALANINAMIDE
N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-Nalpha-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide
NCI60_029010
NSC-681239
NSC681239
PROSCRIPT BORONIC ACID
PS 341
PS-341
Pyz-Phe-boroLeu
S1013_Selleck
SBB071337
Velcade
Velcade (TN)
Velcade, MG-341, PS-341, Bortezomib
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
bortezomib
19
Etanerceptapproved, investigationalPhase 4383185243-69-0
Synonyms:
185243-69-0
CD120b
D00742
Enbrel
Enbrel (TN)
Enbrel Sureclick
Etanercept
Etanercept (USAN/INN)
 
Etanercept (genetical recombination)
Etanercept (genetical recombination) (JAN)
TNF-R2
Tumor necrosis factor receptor 2
Tumor necrosis factor receptor superfamily member 1B precursor
Tumor necrosis factor receptor type II
etanercept
p75
p80 TNF-alpha receptor
20
VindesineapprovedPhase 43759917-39-4, 53643-48-440839
Synonyms:
3-(Aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-(Aminocarbonyl)-O(sup 4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-(aminocarbonyl)-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-Carbamoyl-4-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
3-carbamoyl-O(4)-deacetyl-3-de(methoxycarbonyl)vincaleukoblastine
53643-48-4
AC1L24KY
C43H55N5O7
CHEBI:36373
CHEMBL219146
CID40839
D06304
DAVA
DB00309
Desacetylvinblastine Amide Sulfate
Desacetylvinblastine amide
EINECS 258-682-2
Eldesine
Eldisine
 
HMS2090E15
HSDB 6961
LS-162145
Lilly 112531
MolPort-005-933-570
NSC-245467
STOCK1N-75293
UNII-RSA8KO39WH
Vindesin
Vindesina
Vindesina [INN-Spanish]
Vindesine (USAN/INN)
Vindesine Sulfate
Vindesine [USAN:BAN:INN]
Vindesine [USAN:INN:BAN]
Vindesinum
Vindesinum [INN-Latin]
methyl (5S,7S,9S)-9-[(2b,3b,4b,5a,12b,19a)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate
methyl (5S,7S,9S)-9-[(2beta,3beta,4beta,5alpha,12beta,19alpha)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate
vindesine
21
Aminolevulinic acidapprovedPhase 4, Phase 2142106-60-5137
Synonyms:
106-60-5
35BEC718-C970-426A-9859-BF58284C60B4
5-ALA
5-Amino-4-oxo-Pentanoate
5-Amino-4-oxo-Pentanoic acid
5-Amino-4-oxopentanoate
5-Amino-4-oxopentanoic acid
5-Amino-4-oxovalerate
5-Amino-4-oxovaleric acid
5-Amino-Levulinate
5-Amino-Levulinic acid
5-Aminolaevulinate
5-Aminolaevulinic acid
5-Aminolevulinate
5-Aminolevulinate hydrochloride
5-Aminolevulinic acid
5-amino-levulinate
5451-09-2
AC-054
AC1L18K9
AKOS003587520
ALA
ALA-PDT
Aladerm
Amino-levulinic acid
Aminolevulinate
Aminolevulinic
Aminolevulinic acid
BIDD:GT0260
BSPBio_003407
C00430
CCRIS 8958
CHEBI:17549
CHEMBL601
CID137
CPD000857229
 
D07567
DALA
DB00855
DivK1c_006954
EINECS 203-414-1
I14-10101
KBio1_001898
KBio2_002062
KBio2_004630
KBio2_007198
KBio3_002627
KBioGR_001176
KBioSS_002062
Kerastick
LMFA01100055
LS-101793
Levulan Kerastick
Levulinic acid, 5-amino- (8CI)
MLS001333097
MLS001333098
MolPort-001-788-423
NCGC00178086-01
Pentanoic acid, 5-amino-4-oxo- (9CI)
SAM002589919
SMR000857229
SPBio_001843
ST50819610
SpecPlus_000858
Spectrum2_001662
Spectrum3_001654
Spectrum4_000618
Spectrum5_001505
Spectrum_001582
UNII-88755TAZ87
delta-ALA
delta-Aminolevulinate
delta-Aminolevulinic acid
delta-aminolevulinic acid
22
CrizotinibapprovedPhase 4, Phase 292877399-52-511626560, 10366136, 10366137, 10366138, 10366139, 10366140, 10366141
Synonyms:
(R)-Crizotinib
C-Met/HGFR Tyrosine Kinase Inhibitor PF-02341066
C-Met/Hepatocyte Growth Factor Receptor Tyrosine Kinase Inhibitor PF-02341066
Crizotinib
Crizotinibum
 
MET Tyrosine Kinase Inhibitor PF-02341066
PF 2341066
PF-02341066
PF-2341066
Xalkori
crizotinib
23
CeritinibapprovedPhase 4, Phase 2, Phase 0361032900-25-6
Synonyms:
2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2- isopropylsulfonyl)phenyl) pyrimidine-2,4-diamine
LDK378
 
N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide
Zykadia
céritinib
24
PalbociclibapprovedPhase 4, Phase 185571190-30-211431660, 5005498
Synonyms:
2euf
571190-30-2
6-ACETYL-8-CYCLOPENTYL-5-METHYL-2-[(5-PIPERAZIN-1-YLPYRIDIN-2-YL)AMINO]PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE
6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one
6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one
6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one
AC1NS8RV
CHEMBL189963
CID5330286
EC-000.2350
 
Kinome_3823
Kinome_3824
LQQ
PD 0332991
PD 332991, PD 0332991, PD0332991
PD-0332991
PD-332991
PD0332991
Palbociclib
Palbociclib Isethionate
S1116_Selleck
25
Gefitinibapproved, investigationalPhase 4330184475-35-2123631
Synonyms:
184475-35-2
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
AC-1556
AC1L3X0A
AKOS000280752
BCB03_000781
Bio-0046
C419708
CCRIS 9011
CHEBI:49668
CHEMBL939
CID123631
CU-00000000396-1
D01977
DB00317
DB07998
EC-000.2409
EN002708
FT-0081035
Gefitini
Gefitinib
Gefitinib (JAN/USAN/INN)
Gefitinib [USAN]
Gefitinib, Iressa, ZD1839
HMS2089B19
I01-1227
IRE
 
Iressa
Iressa (TN)
Iressa(TM)
Irressat
K00240
KBioSS_002241
Kinome_3321
Kinome_3322
LS-139916
MolPort-000-883-335
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
NSC715055
S1025_Selleck
STK621310
UNII-S65743JHBS
ZD 1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZD1839
ZINC19632614
gefitinib
nchembio.117-comp18
nchembio866-comp14
26
Lapatinibapproved, investigational, Approved March 2007Phase 4, Phase 2294231277-92-2, 388082-78-8208908, 9941095
Synonyms:
1xkk
231277-92-2
388082-78-8
4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
AB1004631
AC-1314
AC1L4LL4
AKOS005145766
CHEBI:49603
CHEMBL1201179
CHEMBL554
CID11557040
CID208908
D04024
D08108
DB01259
DB02584
EN002712
FMM
GSK 572016
GSK572016
GW 572016
GW 572016X
GW-2016
GW-572016
GW-572016F
GW2016
GW572016
HMS2089H10
I01-1247
 
Kinome_3684
Kinome_3685
LAPATINIB DITOSYLATE MONOHYDRATE
LS-187029
LS-187771
Lapatinib
Lapatinib (INN)
Lapatinib Ditosylate
Lapatinib [INN]
Lapatinib ditosylate
Lapatinib ditosylate (USAN)
Lapatinib tosilate hydrate
Lapatinib tosilate hydrate (JAN)
Lapatinib, Tykerb, GW572016
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine
N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine
N-(3-chloro-4-((3-Fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
NCGC00167507-01
NSC745750
TL80090051
Tycerb
Tykerb
Tykerb (TN)
Tyverb
UNII-0VUA21238F
lapatinib
lapatinib ditosylate
nchembio866-comp20
27AnalgesicsPhase 4, Phase 3, Phase 2, Phase 1, Phase 09358
28Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 017220
29Antiviral AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 08071
30Anti-Retroviral AgentsPhase 4, Phase 3, Phase 2, Phase 12794
31CoagulantsPhase 41042
32Antifungal AgentsPhase 4, Phase 2, Phase 13015
33Antibiotics, AntitubercularPhase 4, Phase 2, Phase 15971
34Angiogenesis InhibitorsPhase 4, Phase 2, Phase 3, Phase 13688
35Angiogenesis Modulating AgentsPhase 4, Phase 2, Phase 3, Phase 13611
36Fibrin Tissue AdhesivePhase 4138
37Anti-Bacterial AgentsPhase 4, Phase 2, Phase 19140
38Analgesics, Non-NarcoticPhase 4, Phase 3, Phase 2, Phase 1, Phase 05184
39
Erlotinib HydrochloridePhase 4, Phase 3, Phase 2, Phase 1781183319-69-9176871
Synonyms:
 
erlotinib hydrochloride
40Poly(ADP-ribose) Polymerase InhibitorsPhase 4, Phase 2, Phase 1250
41Anti-Inflammatory Agents, Non-SteroidalPhase 4, Phase 2, Phase 13549
42Protein Kinase InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Phase 03162
43
ramucirumabPhase 4, Phase 2, Phase 162
Synonyms:
IMC-1121B
 
IMC-3G3
ramucirumab
44Gastrointestinal AgentsPhase 4, Phase 3, Phase 2, Phase 16401
45Immunologic FactorsPhase 4, Phase 3, Phase 2, Phase 1, Phase 018483
46Cholinergic AntagonistsPhase 41423
47Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 018510
48Anti-Inflammatory AgentsPhase 4, Phase 2, Phase 3, Phase 18478
49Imatinib MesylatePhase 4, Phase 1, Phase 2577123596
50Triamcinolone hexacetonidePhase 4, Phase 2, Phase 3448

Interventional clinical trials:

(show top 50)    (show all 1918)
idNameStatusNCT IDPhase
1Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal MelanomaCompletedNCT01253759Phase 4
2Can We Miss Pigmented Lesions in Psoriasis Patients?CompletedNCT01053819Phase 4
3Post-Operative Drainage Following Lymph Node DissectionCompletedNCT00324272Phase 4
4Surgery Versus Radiosurgery to Treat Metastatic Brain TumorsCompletedNCT00075166Phase 4
5Evaluating the Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 TreatmentCompletedNCT00352885Phase 4
6A Study for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node DissectionCompletedNCT02476357Phase 4
7Effect of Topical Imiquimod on Lentigo MalignaCompletedNCT01161888Phase 4
8Characterization of the Melanoma-Specific Immune ResponseRecruitingNCT00368615Phase 4
9Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal AntibodiesRecruitingNCT02626065Phase 4
10Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant MelanomaRecruitingNCT00226473Phase 4
11Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll MelanomaRecruitingNCT02451488Phase 4
12Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.RecruitingNCT01794793Phase 4
13Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing CreamRecruitingNCT02685592Phase 4
14Sentinel Lymph Node Biopsy Findings in Patients With Breast CancerRecruitingNCT02287675Phase 4
15A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.Active, not recruitingNCT02068196Phase 4
16TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam TherapyActive, not recruitingNCT02379000Phase 4
17An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic MelanomaActive, not recruitingNCT01898585Phase 4
18Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque RadiotherapyActive, not recruitingNCT00540930Phase 4
19Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic MelanomaNot yet recruitingNCT02645149Phase 4
20HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic MelanomaTerminatedNCT01683188Phase 4
21HD IL-2 + Ipilimumab in Patients With Metastatic MelanomaTerminatedNCT01856023Phase 4
22Assessment and Tracking of Long-term Alefacept SafetyTerminatedNCT00454701Phase 4
23Genetically-informed Therapies for Patients With Metastatic CancerWithdrawnNCT02000739Phase 4
24MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic MelanomaCompletedNCT00094653Phase 3
25Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00003647Phase 3
26Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With MelanomaCompletedNCT00002882Phase 3
27Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to MelanomaCompletedNCT00324727Phase 3
28Multicenter Selective Lymphadenectomy Trial (MSLT)CompletedNCT00275496Phase 3
29Nordic Adjuvant IFN Melanoma TrialCompletedNCT01259934Phase 3
30A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant MelanomaCompletedNCT00864253Phase 3
31Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in MelanomaCompletedNCT00769704Phase 3
32Trial of Dacarbazine With or Without Genasense in Advanced MelanomaCompletedNCT00518895Phase 3
33Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent MelanomaCompletedNCT00002892Phase 3
34Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV MelanomaCompletedNCT00072124Phase 3
35Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized to Lymph Nodes in the Neck, Under the Arm, or in the GroinCompletedNCT00003444Phase 3
36S0008: Chemotherapy Plus Biological Therapy in Treating Patients With MelanomaCompletedNCT00006237Phase 3
37Sargramostim and/or Vaccine Therapy in Preventing Disease Recurrence in Patients With Advanced MelanomaCompletedNCT01989572Phase 3
38Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node MetastasisCompletedNCT00004196Phase 3
39Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant MelanomaCompletedNCT00016263Phase 3
40A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 MelanomaCompletedNCT00395070Phase 3
41Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant MelanomaCompletedNCT00055562Phase 2, Phase 3
42Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic MelanomaCompletedNCT00003027Phase 3
43Breast and Melanoma Trial With Lymphoseek to Identify Lymph NodesCompletedNCT01106040Phase 3
44An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in MelanomaCompletedNCT01368276Phase 3
45Tumor Infiltrating Lymphocytes Adjuvant Therapy of MelanomaCompletedNCT00200577Phase 3
46Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal MelanomaCompletedNCT00680225Phase 3
47Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)CompletedNCT00091572Phase 3
48Immediate Radiotherapy or Observation After Surgery for Melanoma Involving Lymph NodesCompletedNCT00287196Phase 3
49Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic MelanomaCompletedNCT00019682Phase 3
50Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV MelanomaCompletedNCT00324155Phase 3

Search NIH Clinical Center for Melanoma

Inferred drug relations via UMLS65/NDF-RT43:


Cochrane evidence based reviews: melanoma

Genetic Tests for Melanoma

About this section

Anatomical Context for Melanoma

About this section

MalaCards organs/tissues related to Melanoma:

33
Skin, T cells, Brain, Lymph node, Lung, Breast, Liver

Animal Models for Melanoma or affiliated genes

About this section

Publications for Melanoma

About this section

Articles related to Melanoma:

(show top 50)    (show all 11348)
idTitleAuthorsYear
1
Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. (25169209)
2015
2
EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. (25542448)
2015
3
Pharmacological targeting of guanosine monophosphate synthase suppresses melanoma cell invasion and tumorigenicity. (25909885)
2015
4
Depression, Anxiety, and Regret Before and After Testing to Estimate Uveal Melanoma Prognosis. (26539659)
2015
5
Relationship between rate of posterior uveal melanoma flattening following plaque radiotherapy and GEP class of tumor cells. (24408979)
2014
6
Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclass. (24999598)
2014
7
Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer. (24482145)
2014
8
Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling. (25064638)
2014
9
Radiation-inducible HtrA2 gene enhances radiosensitivity of uveal melanoma OCM-1 cells in vitro and in vivo. (24606398)
2014
10
Thermal sensitisation by lonidamine of human melanoma cells grown at low extracellular pH. (24295212)
2013
11
Melanoma of the sellar region mimicking pituitary adenoma. (22624497)
2013
12
Ocular immune privilege and ocular melanoma: parallel universes or immunological plagiarism? (22707951)
2012
13
RIN1 exhibits oncogenic property to suppress apoptosis and its aberrant accumulation associates with poor prognosis in melanoma. (22627834)
2012
14
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. (21317224)
2011
15
Increases in serum TARC/CCL17 levels are associated with progression-free survival in advanced melanoma patients in response to dendritic cell-based immunotherapy. (19421847)
2009
16
MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. (18316599)
2008
17
PP2A activity is controlled by methylation and regulates oncoprotein expression in melanoma cells: a mechanism which participates in growth inhibition induced by chloroethylnitrosourea treatment. (18097542)
2008
18
Involvement of E-cadherin, beta-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma. (17970806)
2007
19
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. (17545537)
2007
20
Genetic testing for melanoma predisposition: current challenges. (18025917)
2007
21
Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. (16252259)
2006
22
A collision tumor involving Basal cell carcinoma and lentigo maligna melanoma. (16121053)
2005
23
Effect of exogenous wild-type p53 on melanoma cell death pathways induced by irradiation at different linear energy transfer. (16409115)
2005
24
Transforming growth factor-beta and malignant melanoma: molecular mechanisms. (15953371)
2005
25
Unilateral conjunctival-corneal argyrosis simulating conjunctival melanoma. (14557191)
2003
26
Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. (14512791)
2003
27
Ultrasound biomicroscopy in management of malignant iris melanoma. (12742854)
2003
28
A beneficial effect of a short-term formal training course in epiluminescence microscopy on the diagnostic performance of dermatologists about cutaneous malignant melanoma. (12877690)
2003
29
Regulation of CD36 expression in human melanoma cells. (12664607)
2002
30
Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. (11805141)
2002
31
Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis. (11300499)
2001
32
Cyclin-dependent kinase inhibitory protein expression in human choroidal melanoma tumors. (10967035)
2000
33
T cell immune responses against melanoma and melanocytes in cancer and autoimmunity. (11041376)
2000
34
ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. (11084335)
2000
35
Expression of epidermal growth factor receptor: risk factor in uveal melanoma. (10892838)
2000
36
Somatic mutations in the Peutz-Jeghers (LKB1/STKII) gene in sporadic malignant melanomas. (10201537)
1999
37
Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. (10594755)
1999
38
Molecular genetics of familial cutaneous melanoma. (9469357)
1998
39
Development of targeted chemoradiotherapy for malignant melanoma by exploitation of metabolic pathway]. (9612704)
1998
40
Contrasting effects of T cell growth factors on T cell responses to melanoma in vitro. (9067406)
1997
41
Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma. (8826864)
1996
42
Familial uveal melanoma: absence of germline mutations involving the cyclin-dependent kinase-4 inhibitor gene (p16). (8740697)
1996
43
Interferon system defects in human malignant melanoma. (7664286)
1995
44
Stimulation of glycosphingolipid biosynthesis by L-threo-1-phenyl-2-decanoylamino-1-propanol and its homologs in B16 melanoma cells. (7592537)
1995
45
Estramustine binding protein in primary tumours and metastases of malignant melanoma. (7703721)
1994
46
Neuron specific enolase (NSE) in serum of patients with malignant melanoma. (2354416)
1990
47
Effects of tumor promoters on adenylate cyclase activity in melanoma cells in culture. (2244938)
1990
48
Paraneoplastic syndromes, tumor markers, and other unusual features of malignant melanoma. (2869074)
1986
49
Malignant melanomas causing Horner's syndrome in a horse. (3948837)
1986
50
Acral lentiginous melanoma in situ. (7122752)
1982

Variations for Melanoma

About this section

Cosmic variations for Melanoma:

7 (show top 50)    (show all 143)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1COSM476BRAFskin,back,malignant melanoma,superficial spreading7
2COSM520KRASskin,back,malignant melanoma,superficial spreading7
3COSM580NRASskin,back,malignant melanoma,superficial spreading7
4COSM583NRASskin,back,malignant melanoma,superficial spreading7
5COSM584NRASskin,back,malignant melanoma,superficial spreading7
6COSM1116BRAFskin,leg,malignant melanoma,superficial spreading7
7COSM1123BRAFskin,back,malignant melanoma,nodular7
8COSM1137BRAFskin,back,malignant melanoma,superficial spreading7
9COSM1139BRAFskin,back,malignant melanoma,superficial spreading7
10COSM5111PTENskin,leg,malignant melanoma,superficial spreading7
11COSM231627PREX2skin,leg,malignant melanoma,superficial spreading7
12COSM231655PREX2skin,back,malignant melanoma,superficial spreading7
13COSM231663PREX2skin,back,malignant melanoma,superficial spreading7
14COSM231665PREX2skin,leg,malignant melanoma,superficial spreading7
15COSM1651647KITskin,eye,malignant melanoma,NS7
16COSM1756934NF1skin,back,malignant melanoma,nodular7
17COSM1136BRAFskin,back,malignant melanoma,superficial spreading7
18COSM19030APCskin,leg,malignant melanoma,superficial spreading7
19COSM471BRAFskin,NS,malignant melanoma,superficial spreading6
20COSM496HRASskin,NS,malignant melanoma,superficial spreading6
21COSM499HRASskin,NS,malignant melanoma,nodular6
22COSM517KRASskin,NS,malignant melanoma,nodular6
23COSM521KRASskin,NS,malignant melanoma,superficial spreading6
24COSM561NRASskin,NS,malignant melanoma,nodular6
25COSM563NRASskin,NS,malignant melanoma,nodular6
26COSM564NRASskin,NS,malignant melanoma,superficial spreading6
27COSM566NRASskin,NS,malignant melanoma,nodular6
28COSM569NRASskin,NS,malignant melanoma,superficial spreading6
29COSM573NRASskin,NS,malignant melanoma,superficial spreading6
30COSM574NRASskin,NS,malignant melanoma,superficial spreading6
31COSM577NRASskin,NS,malignant melanoma,superficial spreading6
32COSM581NRASskin,upper leg,malignant melanoma,nodular6
33COSM1117BRAFskin,NS,malignant melanoma,nodular6
34COSM1118BRAFskin,NS,malignant melanoma,superficial spreading6
35COSM1119BRAFskin,NS,malignant melanoma,superficial spreading6
36COSM1121BRAFskin,NS,malignant melanoma,nodular6
37COSM1124BRAFskin,NS,malignant melanoma,superficial spreading6
38COSM1134BRAFskin,NS,malignant melanoma,superficial spreading6
39COSM1140BRAFskin,NS,malignant melanoma,superficial spreading6
40COSM1141BRAFskin,NS,malignant melanoma,nodular6
41COSM1142BRAFskin,NS,malignant melanoma,nodular6
42COSM5119PTENskin,NS,malignant melanoma,nodular6
43COSM5142PTENskin,NS,malignant melanoma,superficial spreading6
44COSM5667CTNNB1skin,NS,malignant melanoma,superficial spreading6
45COSM10656TP53skin,NS,malignant melanoma,superficial spreading6
46COSM10867TP53skin,NS,malignant melanoma,nodular6
47COSM12475CDKN2Askin,NS,malignant melanoma,superficial spreading6
48COSM12503CDKN2Askin,NS,malignant melanoma,nodular6
49COSM12506CDKN2Askin,NS,malignant melanoma,superficial spreading6
50COSM13224CDKN2Askin,NS,malignant melanoma,nodular6

Expression for genes affiliated with Melanoma

About this section
Search GEO for disease gene expression data for Melanoma.

Pathways for genes affiliated with Melanoma

About this section

Pathways related to Melanoma according to KEGG:

31
id Name KEGG Source Accession
1Melanomahsa05218

GO Terms for genes affiliated with Melanoma

About this section

Biological processes related to Melanoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cellular senescenceGO:009039810.2MAGEA2, MAGEA2B
2negative regulation of protein sumoylationGO:003323410.1MAGEA2, MAGEA2B

Sources for Melanoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet